- Home
- ANET vs ABBV Comparison
ANET vs ABBV Comparison
Compare ANET & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANET | ABBV |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.5B | 358.5B |
| IPO Year | 2014 | 2012 |
Fundamental Metrics
Financial Performance| Metric | ANET | ABBV |
|---|---|---|
| Price | $156.01 | $222.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 18 |
| Target Price | $175.18 | ★ $253.71 |
| AVG Volume (30 Days) | ★ 9.4M | 3.9M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 3.39% |
| EPS Growth | ★ 23.32 | N/A |
| EPS | ★ 0.80 | 0.39 |
| Revenue | $9,005,700,000.00 | ★ $61,160,000,000.00 |
| Revenue This Year | $29.10 | $11.87 |
| Revenue Next Year | $21.80 | $8.12 |
| P/E Ratio | ★ $192.84 | $582.69 |
| Revenue Growth | ★ 28.60 | 8.57 |
| 52 Week Low | $85.78 | $181.75 |
| 52 Week High | $179.80 | $244.81 |
Technical Indicators
Market Signals| Indicator | ANET | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 49.58 | 60.53 |
| Support Level | $137.42 | $220.11 |
| Resistance Level | $163.81 | $231.00 |
| Average True Range (ATR) | 7.19 | 5.27 |
| MACD | 0.60 | 1.13 |
| Stochastic Oscillator | 46.78 | 64.01 |
Price Performance
Historical ComparisonAbout ANET Arista Networks Inc.
Arista Networks is a networking equipment provider that primarily sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three quarters of its sales from North America.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.